Top Qs
Timeline
Chat
Perspective
Robert Clarke (academic)
Northern Irish_American cancer researcher and academic administrator From Wikipedia, the free encyclopedia
Remove ads
Robert Clarke is a cancer researcher and academic administrator. He is the executive director of The Hormel Institute and a professor of biochemistry, molecular biology and biophysics at the University of Minnesota, and an adjunct professor of oncology at Georgetown University.
With his work focused on breast cancer research, Clarke studies how hormones (endogenous and exogenous) and related factors affect breast cancer. He has authored over 360 publications,[1][2] and he has 5 patents awarded. His research focuses on understanding the endocrine responsiveness of breast cells and the likelihood that breast tumors will respond to specific systemic therapies. His laboratory also studies drug resistance and the role of cell-cell communication in affecting emergence from dormancy and responsiveness to endocrine therapies in breast tumors that express estrogen receptors.[3]
Clarke is an elected fellow of American Association for the Advancement of Science,[4] Royal Society of Chemistry, Royal Society of Medicine, and Royal Society of Biology. He serves on the editorial boards of several journals including Clinical Cancer Research (2006-date),[5] Endocrine-Related Cancer (2012-date)[6] and as associate editor (2001-2007), senior editor (2007-20023) and editorial board member (2023-date) for Cancer Research.[7]
Remove ads
Education
Clarke studied at the University of Ulster and received his bachelor's degree in biological sciences in 1980. He then enrolled at Queen’s University of Belfast and earned a master's degree in 1982 and a PhD in 1986 (each in biochemistry). He completed his postdoctoral training at the Medical Breast Section of the National Cancer Institute in 1988.[8]
Career
Summarize
Perspective
Following his postdoctoral training at National Institutes of Health, Clarke joined Georgetown University School of Medicine as an assistant professor of physiology and biophysics, and was promoted to associate professor of oncology with tenure in 1995, and to professor in 1999. While joining University of Minnesota in 2020, he retains an appointment at Georgetown University as an adjunct professor of oncology. Since 2020, he is a tenured professor of biochemistry, molecular biology and biophysics at University of Minnesota.[9]
Clarke also held several administrative appointments in his career. He served as secretary/treasurer of the Georgetown University Faculty Senate from 2004 until 2007, as associate vice president of Georgetown University Medical Center and director of Biomedical Graduate Research Organization[10] at Georgetown University Medical Center from 2007 till 2019, as co-leader of Breast Cancer Program at Georgetown Lombardi Comprehensive Cancer Center 2006 through 2020, and as dean for research 2011 until 2019 at Georgetown University Medical Center. Since 2020, Clarke serves as executive director of Hormel Institute[8] and member of the executive committee of Masonic Cancer Center[11] at University of Minnesota.
Remove ads
Research
Summarize
Perspective
Clarke's work is focused on how hormones (endogenous and exogenous) and related factors affect breast cancer. He focused initially on the interactions of hormones and anticancer drugs, and then expanded the work into studies of the underlying cellular and molecular mechanisms that explain how breast cancers become resistant to hormone and cytotoxic therapies. Clarke and his colleagues developed a series of hormone resistant breast cancer models that are now used in the field.[12] [13][14][15]
Breast cancer
As a systems and integrative cancer biology researcher,[16] Clarke’s research team and collaborators discovered a new signaling network and control mechanism that contributes to the hormonal regulation of breast cancer cell proliferation and cell death in response to estrogens and other endocrine therapies.[17][18][19] This signaling includes communication between the endoplasmic reticulum and mitochondria, and reflects novel interactions within the unfolded protein response. His group has also identified interferon regulatory factor-1 as a breast cancer suppressor gene,[20][21] and worked on the development and application of genomic and novel bioinformatic methods in translational breast cancer studies.[22][23] Clarke also contributed to establishing the role of maternal diet in mammary gland development and breast cancer risk,[24] the concept of metalloestrogens,[25] the importance of continued expression of the estrogen receptor in endocrine resistance,[19] and completed one of the first radiogenomic studies of breast cancer [23] and meta-analyses of the role of soy exposure in breast cancer. [26]
Endocrine resistance in breast cancer
Clarke identified some of the first non-nuclear activities of endocrine therapies including the effects of Tamoxifen and high dose estrogens on membrane fluidity.[27] In his studies of drug resistance and MDR1/P-glycoprotein,[28] he published the first statistical meta-analysis of the role of MDR1 in breast cancer,[29][30] and defined novel mechanisms of resistance to Taxanes.[31][32] He was among the pioneers to implicate the unfolded protein response (UPR) in acquired endocrine resistance[18][33] and in regulating involution in the normal mammary gland.[34] In addition, his research team implicated key BCL2 family members, interferon regulatory factor-1 and NFκB in endocrine resistance,[33] and defined basic interactions among the UPR, autophagy and apoptosis,[35] regulation of immune markers,[36] and the role for epigenetic changes in determining trans-generational effects on endocrine responsiveness in breast cancer.[37]
In his studies on the endocrine-mediated regulation of breast cancer progression and cell fate, he explored the concept that endocrine resistance reflects cell state transitions,[38] where the transitions reflect integrated and adaptive signaling that includes control of endoplasmic reticulum, mitochondrial and nuclear functions. Together, this signaling is represented in a modular network that regulates and executes five key cell function modules (autophagy, cell death, metabolism, proliferation, and UPR).[17][18][39]
Remove ads
Awards and honors
Bibliography
- Clarke, R., Brünner, N., Katzenellenbogen, B.S., Thompson E.W., Norman, M.J., Koppi, C., Paik, S., Lippman, M.E. & Dickson, R.B. (1989). Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proceedings of the National Academy of Sciences USA, 86(10), 3649–3653. PMID 2726742
- Trock, B. J., Leonessa, F., & Clarke, R. (1997). Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. Journal of the National Cancer Institute, 89(13), 917–931. PMID 1359153
- Trock, B. J., Hilakivi-Clarke, L., & Clarke, R. (2006). Meta-analysis of soy intake and breast cancer risk. Journal of the National Cancer Institute, 98(7), 459–471. PMID 16595782
- Clarke, R., Ressom, H. W., Wang, A., Xuan, J., Liu, M. C., Gehan, E. A., & Wang, Y. (2008). The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nature Reviews Cancer, 8(1), 37–49. PMID 18097463
- Tyson, J.J., Baumann, W.T., Chen, C., Verdugo, A., Tavassoly, I., Wang, Y., Weiner, L.M. & Clarke, R. (2011). Dynamic modelling of estrogen signaling and cell fate in breast cancer cells. Nature Reviews Cancer, 11(7): 523–532. PMID 21677677
- O’Sullivan CC, Clarke R, Goetz MP & Robertson JF. Cyclin Dependent 4/6 Kinase inhibitors for treatment of hormone receptor positive, HER2-negative breast cancer: past successes, current challenges, and future directions. JAMA Oncology, 9: 1273-1282, 2023. PMID 37382948
- Korangath P, Jin L, Yang C-T, Healy S, Guo X, Ke S, Hu C, Gabrielson K, Foote J, Clarke, R. & Ivkov, R. Iron oxide nanoparticles inhibit tumor progression and suppress lung metastases in mouse models of breast cancer. ACS Nano 18:10509-10526, 2024. PMID 38564478
- Farsani SSM, Soni J, Jin L, Yadav AK, Bansal S, Mi T, Hilakivi-Clarke LA, Clarke R, Youngblood B, Cheema A. & Verma V. Pyruvate kinase M2 reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy, . Cell Metabolism, S1550-4131(25)00106-8, 2025. PMID: 40199327
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads